Teva builds its Mylan stake in effort toward becoming generics colossus

Teva ($TEVA) is upping its pressure on takeover target Mylan ($MYL) as the world's largest generics maker continues its march toward turning itself into a generics colossus. This week, Teva increased its stake in Mylan, which has resisted Teva's offers. It now has control of more than 3% of Mylan's shares, giving it enough leverage to submit agenda items at a shareholder meeting next quarter, seen as pivotal in its takeover attempt. Mylan has said it doesn't think antitrust regulators would approve a merger of Teva and Mylan, but Teva claims it has explored that concern and is confident it could. More from FiercePharma

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.